Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study
et al., J. Infection, doi:10.1016/j.jinf.2021.02.011
, Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study, J. Infection, doi:10.1016/j.jinf.2021.02.011
Lopinavir/ritonavir retrospective study also showing univariate results for HCQ, with significantly lower mortality.
|
risk of death, 50.5% lower, RR 0.50, p < 0.001, treatment 7,192, control 1,361, odds ratio converted to relative risk, univariate, control prevalence approximated with overall prevalence.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Lora-Tamayo et al., 11 Feb 2021, retrospective, Spain, peer-reviewed, 10 authors.
Abstract: Journal of Infection 82 (2021) 276–316
Contents lists available at ScienceDirect
Journal of Infection
journal homepage: www.elsevier.com/locate/jinf
Letters to the Editor
Short durations of corticosteroids for hospitalised
COVID-19 patients are associated with a high readmission
rate
Dear Editor,
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.